https://digital.library.adelaide.edu.au/dspace/bitstream/2440/98611/2/hdl_98611.pdf

Designing a broad-spectrum integrative approach for cancer prevention and treatment

Introduction: Throughout history, natural products (NPs) have provided a rich source of compounds that have wide applications in the fields of medicine, health sciences, pharmacy and biology. Although naturally active substances are good lead compounds for the discovery of new drugs, most of them suffer from various deficiencies or shortcomings, such as complex structures, poor stability and solubility. Therefore, structural modification of NPs is needed to develop novel compounds with specific properties.Areas covered: This article presents an overview on the structural modifications of NPs in drug development. The application of multiple classes of NPs to the treatment of conditions such as cancers, infection, Alzheimer’s and diabetes are discussed. This article also reveals that modification of NPs is a versatile approach to explore their mode of actions, which may lead to the discovery of novel drugs.Expert opinion: NPs are usually described by structural diversity and complexity. The use of i...

The structural modification of natural products for novel drug discovery.

Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts

Background: Nowadays, the functional foods represent one the most promising, interesting and innovativeareas in the food industry. Various components are being added to foods in order to render them functional.Methods: One example of these components are plant naturally occurring phenolic compounds, which are associatedwith a high antioxidant capacity and thus with benefits in relation to human health.Results: However, despite the huge number of scientific studies and patents on this topic and their natural presencein foods, namely in the ones from plant origin, there are still few marketable products enriched with thesecompounds. The commercialization of this type of functional products needs to go through various regulations,proving that they are safe and present the ascribed health benefits, conquering the target audience. In this reviewthe growing interest of industry and consumers’ appetence for functional foods and nutraceuticals is highlighted,focusing especially on phenolic compounds.Conclusion: Although several published works show the multitude of bioactive properties of these compounds,ensuring their use as bioactive ingredients in food, they present inherent stability issues needing to be solved.However, considerable research is presently ongoing to overcome this problem, making viable the developmentof new products to be launched in the market.

/pdf/phenolic-compounds-as-nutraceuticals-or-functional-food-wtca9xz3no.pdf

Phenolic Compounds as Nutraceuticals or Functional Food Ingredients.

Genetically modified foods in China and the United States: A primer of regulation and intellectual property protection

Regulations and protection for functional food products in the United States

Extracts and compounds of natural products have potential as alternatives to current Western medicines. However, these products may not be patentable under the statutory requirements because of their naturally-occurring nature. This article analyzes the current patenting practices for natural products in the United States, particularly in light of the recent Supreme Court ruling in Myriad, and suggests an advantageous strategy for patenting these products. Briefly, isolated natural products per se are not patentable in the United States. Therefore, patenting focus should be placed on the modification, formulation, manufacture, and application of natural products. A detailed description of each invention is highly recommended for stronger support and broader coverage of the claims.

/pdf/myriad-and-its-implications-for-patent-protection-of-26s2hk81x0.pdf

Myriad and its implications for patent protection of isolated natural products in the United States

Many first-generation biologics will lose their patent protection by 2020. The biosimilars market is not only attractive but also competitive and tough. The United States (US) is the world's largest pharmaceutical market and is critical to the success of most drugs. However, unclear regulatory requirements and confusing patent resolution procedures create hurdles to market entry of biosimilars. Trade secret exposure and scant exclusivity and adoption also limit the market access of biosimilars. Both biologics and biosimilar developers should closely follow the regulatory and litigation landscape to successfully navigate through the challenges. Focusing on the US landscape, this article provides a brief review of the regulatory framework for biosimilar products, market exclusivities, and patent issues under the Biologics Price Control and Innovation Act (BPCIA), analyzes emerging issues in the biosimilar litigation landscape, and provides recommendations for companies entering the biosimilars market.

Biosimilars in the United States: Emerging Issues in Litigation

What are the implications of recent US Supreme Court decisions on the patent eligibility of stem cells?

/pdf/a-patent-perspective-on-us-stem-cell-research-3bwxxxw6l6.pdf

Alice Yuen-Ting Wong

Papers

Genetically modified foods in China and the United States: A primer of regulation and intellectual property protection

Regulations and protection for functional food products in the United States

Myriad and its implications for patent protection of isolated natural products in the United States

Biosimilars in the United States: Emerging Issues in Litigation

A patent perspective on US stem cell research